You are not logged in.
Openly accessible

Advances in medical revascularisation treatments in acute ischemic stroke

Asadi, Hamed, Yan, B, Dowling, R, Wong, S and Mitchell, P 2014, Advances in medical revascularisation treatments in acute ischemic stroke, Thrombosis, vol. 2014, pp. 1-14, doi: 10.1155/2014/714218.

Attached Files
Name Description MIMEType Size Downloads
asadi-advancesinmedical-2014.pdf Published version application/pdf 337.42KB 3

Title Advances in medical revascularisation treatments in acute ischemic stroke
Author(s) Asadi, HamedORCID iD for Asadi, Hamed orcid.org/0000-0003-2475-9727
Yan, B
Dowling, R
Wong, S
Mitchell, P
Journal name Thrombosis
Volume number 2014
Article ID 714218
Start page 1
End page 14
Total pages 14
Publisher Hindawi Publishing Corporation
Place of publication Cairo, Egypt
Publication date 2014
ISSN 2090-1488
Keyword(s) Ischaemic brain
Acute ischemic stroke
Stroke treatment
Vessel recanalisation
tPA
Medical therapy
Summary Urgent reperfusion of the ischaemic brain is the aim of stroke treatment and there has been ongoing research to find a drug that can promote vessel recanalisation more completely and with less side effects. In this review article, the major studies which have validated the use and safety of tPA are discussed. The safety and efficacy of other thrombolytic and anticoagulative agents such as tenecteplase, desmoteplase, ancrod, tirofiban, abciximab, eptifibatide, and argatroban are also reviewed. Tenecteplase and desmoteplase are both plasminogen activators with higher fibrin affinity and longer half-life compared to alteplase. They have shown greater reperfusion rates and improved functional outcomes in preliminary studies. Argatroban is a direct thrombin inhibitor used as an adjunct to intravenous tPA and showed higher rates of complete recanalisation in the ARTTS study with further studies which are now ongoing. Adjuvant thrombolysis techniques using transcranial ultrasound are also being investigated and have shown higher rates of complete recanalisation, for example, in the CLOTBUST study. Overall, development in medical therapies for stroke is important due to the ease of administration compared to endovascular treatments, and the new treatments such as tenecteplase, desmoteplase, and adjuvant sonothrombolysis are showing promising results and await further large-scale clinical trials.
Language eng
DOI 10.1155/2014/714218
Field of Research 110399 Clinical Sciences not elsewhere classified
Socio Economic Objective 929999 Health not elsewhere classified
HERDC Research category C1.1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2014, H. Asadi et al
Free to Read? Yes
Use Rights Creative Commons Attribution licence
Persistent URL http://hdl.handle.net/10536/DRO/DU:30092714

Document type: Journal Article
Collections: School of Medicine
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 8 Abstract Views, 3 File Downloads  -  Detailed Statistics
Created: Mon, 03 Apr 2017, 12:25:37 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.